Good morning, welcome to Lexeo Therapeutics 2026 Annual Meeting of Stockholders. I am Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics and a member of its Board of Directors. I will preside as Chair of this meeting, which I now call to order. With us today are members from management, including Louis Tamayo, our Chief Financial Officer and Corporate Secretary, Youjin Choi, our Vice President, Assistant General Counsel, and Ryan McHenry, our Vice President, Corporate Controller. Also with us are members of our Board of Directors and Harry Cohen of KPMG LLP, our independent public accountants, Megan Baier of Wilson Sonsini Goodrich & Rosati, our outside corporate counsel, Kathryn Wheadon of The Carideo Group, who has been appointed Inspector of Election for this meeting and has signed an oath of office which will be filed with the minutes of this meeting. Now I would like to turn the formal portion of the meeting over to Louis Tamayo, our Chief Financial Officer. Louis will act as Secretary of the Meeting and keep the minutes. Thanks, Nolan. The agenda and rules of conduct for today's meeting are posted on the virtual meeting website. Please abide by the rules of conduct in order to facilitate an orderly meeting and allow us to accomplish the items on the agenda. In today's meeting, we will address and vote on the proposals described in the company's proxy statement dated April 30th, 2026. Following the vote, we will announce the preliminary results and then adjourn the formal meeting. After we adjourn, we will provide time to answer appropriate questions from stockholders. Only validated stockholders may ask questions in the designated field on the meeting website. Questions may be submitted at any time during the meeting and prior to the end of the Q&A session. I have an affidavit certifying that notice of this meeting was duly given and that the proxy materials for this meeting were made available on or about April 30th, 2026, to all stockholders of record as of the close of business on May 7th, 2026, which was the record date for this meeting. As of the record date, there were 78,521,634 shares of Lexeo Therapeutics common stock outstanding and entitled to vote on each proposal presented at this meeting. A complete list of the stockholders of record as of the record date has been prepared and certified by our registrar and transfer agent and is available for inspection on the meeting website. The inspector of election has advised me that we have present in person or by proxy a sufficient number of shares to constitute the quorum necessary to proceed with this meeting. Turning to voting procedures, we will vote today via the meeting website. Please note that if you logged into the meeting website as a guest, you will not be able to vote during the meeting. If you previously voted via telephone or internet or by returning a proxy card and do not intend to change your vote, it is not necessary to take further action as the vote you already cast will be counted. If you are eligible to vote and have not done so, or if you want to change your vote, you may vote by clicking on the voting button on the meeting website and following the instructions there. Any votes cast today will be counted in the final tally along with the proxies previously received. If you would like to ask a question regarding any of the proposals or voting procedures, please submit your questions through the meeting website. As set forth in the notice of meeting, there are two proposals properly before this meeting today. The first proposal is to elect R. Nolan Townsend, Brenda Cooperstone, and Paula H.J. Cholmondeley as Class III directors, each to hold office for a three-year term expiring in 2029, or until their respective successors have been duly elected and qualified. The second proposal is to ratify the appointment of KPMG LLP as the company's independent registered public accounting firm for the current fiscal year ending December 31st, 2026. Lexeo Therapeutics Board of Directors recommends that you vote in favor of each of these proposals. I can confirm that no questions have been submitted relating to the proposals. We can now turn to the polls. The polls are open for voting. Those of you who are voting today should vote on the meeting website now. Upon the closing of the polls, no ballots, proxies, votes, or any revocations or changes will be accepted. I will pause at this time to allow stockholders to complete any online voting. I hereby declare the polls closed. Ms. Wheadon, will you please report on the preliminary results of the voting? Mr. Tamayo, based on the proxies received prior to the meeting and subject to final adjustment for any votes made during the meeting, I can report that R. Nolan Townsend, Brenda Cooperstone, and Paula H.J. Cholmondeley have been duly elected to the board as Class III directors, and the proposal to ratify KPMG LLP as Lexeo Therapeutics' independent auditor passed. Thank you, Ms. Wheadon. The inspector of election will conduct a final count of all votes, we will announce final results in our current report on Form 8-K to be filed within four business days of this meeting. Thank you, Louis and Ms. Wheadon. That concludes the official business of the meeting, I declare the meeting adjourned. We will now respond to appropriate stockholder questions that have been submitted. We will attempt to answer as many questions as time allows, only questions that follow the rules of conduct will be addressed. Please note that federal securities laws prohibit us from providing any material non-public information in this forum. If any questions touch on material non-public information, we will not be able to address those questions. Louis, have we received any questions that are in compliance with the rules of conduct? Nolan, there are no questions to address. Thank you all for attending the meeting today and for your continued support of Lexeo Therapeutics. This concludes today's meeting. Thank you for your participation. You may now disconnect.